Delahaye S - Search Results

1

Effectiveness and complications of ultrasound-guided subclavian vein cannulation in children and neonates.

Nardi N, Wodey E, Laviolle B, De La Brière F, Delahaye S, Engrand C, Gauvrit C, Dessard S, Defontaine A, Ecoffey C. Nardi N, et al. Among authors: delahaye s. Anaesth Crit Care Pain Med. 2016 Jun;35(3):209-13. doi: 10.1016/j.accpm.2015.09.007. Epub 2016 Feb 26. Anaesth Crit Care Pain Med. 2016. PMID: 26924612 Free article.

2

Alkalinization of intra-cuff lidocaine and use of gel lubrication protect against tracheal tube-induced emergence phenomena.

Estebe JP, Delahaye S, Le Corre P, Dollo G, Le Naoures A, Chevanne F, Ecoffey C. Estebe JP, et al. Among authors: delahaye s. Br J Anaesth. 2004 Mar;92(3):361-6. doi: 10.1093/bja/aeh078. Br J Anaesth. 2004. PMID: 14970135 Free article. Clinical Trial.

3

Whole-body MR imaging in suspected physical child abuse: comparison with skeletal survey and bone scintigraphy findings from the PEDIMA prospective multicentre study.

Proisy M, Vivier PH, Morel B, Bruneau B, Sembely-Taveau C, Vacheresse S, Devillers A, Lecloirec J, Bodet-Milin C, Dubois M, Hamonic S, Bajeux E, Ganivet A, Adamsbaum C, Treguier C; PEDIMA study research group. Proisy M, et al. Eur Radiol. 2021 Nov;31(11):8069-8080. doi: 10.1007/s00330-021-07896-9. Epub 2021 Apr 29. Eur Radiol. 2021. PMID: 33912993

4

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, Durand M, Rieux V, Diallo A, Lacabaratz C, Cardinaud S, Zurawski S, Zurawski G, Tomaras GD, Ding S, Centlivre M, Thiebaut R, Pantaleo G, Lelièvre JD, Richert L; ANRS VRI06 Study Group. Levy Y, et al. EClinicalMedicine. 2024 Oct 2;77:102845. doi: 10.1016/j.eclinm.2024.102845. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39649135 Free PMC article.

5

Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity.

Hubler F, Renneberg D, Siendt H, Stamm S, Hilpert K, Caroff E, Delahaye S, Froidevaux S, Murphy MJ. Hubler F, et al. Among authors: delahaye s. J Med Chem. 2024 Mar 14;67(5):4100-4119. doi: 10.1021/acs.jmedchem.3c02375. Epub 2024 Mar 4. J Med Chem. 2024. PMID: 38482828

6

Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases.

Lescop C, Birker M, Brotschi C, Bürki C, Morrison K, Froidevaux S, Delahaye S, Nayler O, Bolli MH. Lescop C, et al. Among authors: delahaye s. J Med Chem. 2024 Feb 22;67(4):2397-2424. doi: 10.1021/acs.jmedchem.3c01827. Epub 2024 Feb 13. J Med Chem. 2024. PMID: 38349250

7

Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold.

Lescop C, Brotschi C, Williams JT, Sager CP, Birker M, Morrison K, Froidevaux S, Delahaye S, Nayler O, Bolli MH. Lescop C, et al. Among authors: delahaye s. J Med Chem. 2024 Feb 22;67(4):2379-2396. doi: 10.1021/acs.jmedchem.3c01826. Epub 2024 Feb 13. J Med Chem. 2024. PMID: 38349223

8

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivo.

Anliker-Ort M, Dingemanse J, Delahaye S, Janů L, van den Anker J, Berger B, Kaufmann P. Anliker-Ort M, et al. Among authors: delahaye s. Clin Transl Sci. 2023 Jul;16(7):1220-1231. doi: 10.1111/cts.13525. Epub 2023 Apr 26. Clin Transl Sci. 2023. PMID: 37042126 Free PMC article.

9

CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4-Hydroxypiperidinol Metabolites.

Treiber A, Aissaoui H, Delahaye S, Glutz S, Grimont J, Müller C, Seeland S, Siefken V, Boss C. Treiber A, et al. Among authors: delahaye s. ChemMedChem. 2023 May 16;18(10):e202300030. doi: 10.1002/cmdc.202300030. Epub 2023 Apr 12. ChemMedChem. 2023. PMID: 36892179

10

The metabolism of the dual orexin receptor antagonist daridorexant.

Treiber A, Delahaye S, Weigel A, Aeänismaa P, Gatfield J, Seeland S. Treiber A, et al. Among authors: delahaye s. Xenobiotica. 2023 Mar;53(3):173-183. doi: 10.1080/00498254.2023.2183159. Epub 2023 May 11. Xenobiotica. 2023. PMID: 36809238

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters